Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry.
about
Mass spectrometry for the assessment of the occurrence and biological consequences of DNA adductsSalvage of oxidized guanine derivatives in the (2'-deoxy)ribonucleotide pool as source of mutations in DNA.Quantitation of DNA adducts by stable isotope dilution mass spectrometry.Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells.Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.
P2860
Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Towards biomarker-dependent in ...... accelerator mass spectrometry.
@ast
Towards biomarker-dependent in ...... accelerator mass spectrometry.
@en
type
label
Towards biomarker-dependent in ...... accelerator mass spectrometry.
@ast
Towards biomarker-dependent in ...... accelerator mass spectrometry.
@en
prefLabel
Towards biomarker-dependent in ...... accelerator mass spectrometry.
@ast
Towards biomarker-dependent in ...... accelerator mass spectrometry.
@en
P2093
P2860
P1476
Towards biomarker-dependent in ...... accelerator mass spectrometry.
@en
P2093
Kenneth W Turteltaub
Paul T Henderson
Sang Soo Hah
P2860
P304
P356
10.1016/J.BMCL.2010.03.020
P407
P577
2010-03-07T00:00:00Z